Harvard Bioscience (HBIO) Share-based Compensation (2010 - 2026)

Harvard Bioscience (HBIO) has reported Share-based Compensation for 17 consecutive years, with $2.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Share-based Compensation rose 224.5% year-over-year to $2.3 million in Q2 2026; TTM through Jun 2026 was $2.3 million, a 224.5% increase from a year earlier, with the FY2025 full-year figure at $1.9 million, down 57.26% from the prior year.
• Share-based Compensation was $2.3 million for Q2 2026 at Harvard Bioscience, up from $2.2 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $7.8 million in Q2 2024 and troughed at $459000.0 in Q4 2025.
• A 5-year average of $2.5 million and a median of $1.4 million in 2022 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation jumped 444.4% in 2023 and tumbled 90.91% in 2025, its largest moves.
• Over 5 years, Share-based Compensation stood at $1.0 million in 2022, then jumped by 36.83% to $1.4 million in 2023, then sank by 30.46% to $961000.0 in 2024, then tumbled by 52.24% to $459000.0 in 2025, then surged by 401.09% to $2.3 million in 2026.
• The last three Share-based Compensation figures came in at $2.3 million (Q2 2026), $2.2 million (Q1 2026), and $459000.0 (Q4 2025), per Business Quant data.